The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
UK researchers found that just 22 percent of screening recommendations for rare newborn diseases were based on systematic reviews of available evidence.
The USPSTF said that men aged 55 to 69 should decide in discussions with their clinicians whether to undergo periodic PSA screening.
Practice recommendations could serve as a guide for labs considering using the high-sensitivity assays as they become available, authors said.
BD and the FDA said that a chemical called thiuram found in certain BD blood collection tubes may render results from Magellan's LeadCare blood lead tests inaccurate.
The new Kidney Profile combines two existing tests for chronic kidney disease and could be critical in addressing the under-diagnosis of the ailment.
Currently available screening methods have not been shown to reduce mortality in the general population, USPSTF said.
The so-called ACT sheets are one pagers that guide doctors on what to do after receiving a genetic test results for a patient.
The group that advises primary care clinicians found evidence that false-positive screening results could lead to surgical interventions in asymptomatic patients.
The guidance recommends microsatellite instability testing or immunohistochemistry be used to detect abnormalities that may lead to Lynch syndrome.